Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherBrowse by ChannelAbout the NetworkJoin the NetworkProductsSub-MenuProducts OverviewBlog ProBlog PlusBlog PremierMicrositeSyndication PortalsAbout UsContactSubscribeSupport
Book a Demo
Search
Close

Celltrion Adalimumab Biosimilar Granted Interchangeability Designation

April 18, 2025

EU Biosimilar Regulatory and Launch Updates

February 7, 2025

Amgen Files BPCIA Complaint Against Accord Biopharma Regarding Denosumab Biosimilar

November 18, 2024

FDA Approves Ustekinumab, Aflibercept, and Filgrastim Biosimilars

July 9, 2024

Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab

June 5, 2024

Alexion Sues Samsung over Proposed Eculizumab Biosimilar

January 17, 2024

FDA Approves LOQTORZI in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

October 31, 2023

Scheduling Order Issued in REGENXBIO v. Sarepta Litigation

September 27, 2023

Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patent

August 22, 2023

FDA Accepts BLA for Dr. Reddy’s Rituximab Biosimilar for Review

July 21, 2023

Post navigation

Older Posts 
Subscribe: Subscribe via RSS
Blogs
  • Big Molecule Watch
Firm/Org
  • Goodwin Procter

Zachariah Holmes

Subscribe: Subscribe via RSS
Blogs
  • Big Molecule Watch
Firm/Org
  • Goodwin Procter
LexBlog, Inc. logo
Facebook LinkedIn Twitter RSS
Real Lawyers
99 Park Row
  • About LexBlog
  • Careers
  • Press
  • Contact LexBlog
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Terms of Service
  • RSS Terms of Service
  • Products
  • Blog Pro
  • Blog Plus
  • Blog Premier
  • Microsite
  • Syndication Portals
  • LexBlog Community
  • Resource Center
  • 1-800-913-0988
  • Submit a Request
  • Support Center
  • System Status
  • Resource Center
  • Blogging 101

New to the Network

  • Tennessee Insurance Litigation Blog
  • Claims & Sustains
  • New Jersey Restraining Order Lawyers
  • New Jersey Gun Lawyers
  • Blog of Reason
Copyright © 2025, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo